Last Decade Research on RCC in figures
Ruíz-Morales JM, et al. Eur J Cancer 2016
Motzer RJ, et al. J Clin Oncol 1999
•
Only 2 drugs (IL-2 and INF
⍺
) were approved worldwide in 2005
•
Today, up to 11 agents are approved by EMA
•
Median survival improved from 13 till 22 months in daily practice
•
6 additional compounds are now in phase III seeking the approval
•
1.622 clinical trials are registered in the field
